Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Ovarian Neoplasms

Free Subscription 29.10.2018 2 BMC Cancer 2 Br J Cancer 8 Gynecol Oncol 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

BMC Cancer

1. GAO T, Yu Y, Cong Q, Wang Y, et al
   Human mesenchymal stem cells in the tumour microenvironment promote ovarian cancer progression: the role of platelet-activating factor.
   BMC Cancer. 2018;18:999.
   PubMed     Text format     Abstract available
   
   
2. ARORA N, Talhouk A, McAlpine JN, Law MR, et al
   Long-term mortality among women with epithelial ovarian cancer: a population-based study in British Columbia, Canada.
   BMC Cancer. 2018;18:1039.
   PubMed     Text format     Abstract available
   
   

   
   Br J Cancer

3. FRIEDLANDER M, Matulonis U, Gourley C, du Bois A, et al
   Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
   Br J Cancer. 2018 Oct 24. pii: 10.1038/s41416-018-0271.
   PubMed     Text format     Abstract available
   
   
4. HODGSON DR, Dougherty BA, Lai Z, Fielding A, et al
   Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
   Br J Cancer. 2018 Oct 24. pii: 10.1038/s41416-018-0274.
   PubMed     Text format     Abstract available
   
   

   
   Gynecol Oncol

5. BARNARD ME, Pyden A, Rice MS, Linares M, et al
   Inter-pathologist and pathology report agreement for ovarian tumor characteristics in the Nurses' Health Studies.
   Gynecol Oncol. 2018 Jul 9. pii: S0090-8258(18)31016.
   PubMed     Text format     Abstract available
   
   
6. BI Y, Verginadis II, Dey S, Lin L, et al
   Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas.
   Gynecol Oncol. 2018 Jul 16. pii: S0090-8258(18)31015.
   PubMed     Text format     Abstract available
   
   
7. NISHIKIMI K, Tate S, Matsuoka A, Shozu M, et al
   Metastatic cardiophrenic lymph node resection following full-thickness resection of right diaphragm for advanced ovarian carcinoma.
   Gynecol Oncol. 2018 Jul 19. pii: S0090-8258(18)31067.
   PubMed     Text format     Abstract available
   
   
8. MEAGHER NS, Schuster K, Voss A, Budden T, et al
   Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
   Gynecol Oncol. 2018 Jul 24. pii: S0090-8258(18)31077.
   PubMed     Text format     Abstract available
   
   
9. VERGOTE I, von Moos R, Manso L, Van Nieuwenhuysen E, et al
   Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study.
   Gynecol Oncol. 2018 Jul 27. pii: S0090-8258(18)31082.
   PubMed     Text format     Abstract available
   
   
10. SONG M, Kumaran MN, Gounder M, Gibbon DG, et al
    Phase I trial of selenium plus chemotherapy in gynecologic cancers.
    Gynecol Oncol. 2018 Jul 29. pii: S0090-8258(18)31014.
    PubMed     Text format     Abstract available
    
    
11. TANNER EJ, Filippova OT, Gardner GJ, Long Roche KC, et al
    A prospective trial of acute normovolemic hemodilution in patients undergoing primary cytoreductive surgery for advanced ovarian cancer.
    Gynecol Oncol. 2018 Oct 15. pii: S0090-8258(18)31285.
    PubMed     Text format     Abstract available
    
    
12. OLAWAIYE AB, Java JJ, Krivak TC, Friedlander M, et al
    Corrigendum to "Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study" [Gynecol. Oncol. 151 (2018) 18-23].
    Gynecol Oncol. 2018 Oct 22. pii: S0090-8258(18)31303.
    PubMed     Text format    
    
    

    
    PLoS One

13. ZHENG G, Yu H, Kanerva A, Forsti A, et al
    Correction: Familial risks of ovarian cancer by age at diagnosis, proband type and histology.
    PLoS One. 2018;13:e0206721.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: